Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVD908ssb-TXSVN
- Development stage
- Phase 1
- Lead developer
- Baylor College of Medicine
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
CVD908ssb-TXSVN (also known as TXSVN) is an investigational, orally administered cancer vaccine developed by the Baylor College of Medicine. It consists of a live-attenuated strain of *Salmonella enterica* serovar Typhi (CVD 908-ssb) that has been genetically engineered to express the tumor-associated antigen (TAA) survivin (BIRC5). Survivin is a member of the inhibitor of apoptosis (IAP) protein family that is highly overexpressed in most human malignancies, including multiple myeloma, but is minimally expressed in normal adult tissues. By utilizing the natural tropism of Salmonella for gut-associated lymphoid tissue (GALT), the vaccine is designed to stimulate a systemic T-cell-mediated immune response against survivin-expressing tumor cells. The CVD 908-ssb vector itself is a well-characterized live-attenuated strain containing deletions in the *aroC*, *aroD*, and *htrA* genes to ensure safety while maintaining immunogenicity.
- Other names
- Salmonella-based survivin vaccineTXSVN vaccineCVD 908-ssb-TXSVNCVD908-ssb-TXSVNCVD-908-ssb-TXSVN
02
Targets
BIRC5 (Survivin)
Beyond the preview
Go deeper on CVD908ssb-TXSVN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVD908ssb-TXSVN.